Kian-Huat Lim
Kian-Huat Lim
Washington University School of Medicine
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Oncogenically active MYD88 mutations in human lymphoma
VN Ngo, RM Young, R Schmitz, S Jhavar, W Xiao, KH Lim, ...
Nature 470 (7332), 115-119, 2011
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a …
TM Nywening, A Wang-Gillam, DE Sanford, BA Belt, RZ Panni, ...
The lancet oncology 17 (5), 651-662, 2016
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis
B Ancrile, KH Lim, CM Counter
Genes & development 21 (14), 1714-1719, 2007
Toll-like receptor signaling
KH Lim, LM Staudt
Cold Spring Harbor perspectives in biology 5 (1), a011247, 2013
Activation of RalA is critical for Ras-induced tumorigenesis of human cells
KH Lim, AT Baines, JJ Fiordalisi, M Shipitsin, LA Feig, AD Cox, CJ Der, ...
Cancer cell 7 (6), 533-545, 2005
RALA and RALBP1 regulate mitochondrial fission at mitosis
DF Kashatus, KH Lim, DC Brady, NLK Pershing, AD Cox, CM Counter
Nature cell biology 13 (9), 1108-1115, 2011
Tumour maintenance is mediated by eNOS
KH Lim, BB Ancrile, DF Kashatus, CM Counter
Nature 452 (7187), 646-649, 2008
The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis
YS Lee, KH Lim, X Guo, Y Kawaguchi, Y Gao, T Barrientos, P Ordentlich, ...
Cancer research 68 (18), 7561-7569, 2008
Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells
KH Lim, K O'Hayer, SJ Adam, SDS Kendall, PM Campbell, CJ Der, ...
Current Biology 16 (24), 2385-2394, 2006
Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance
KH Lim, CM Counter
Cancer cell 8 (5), 381-392, 2005
Pathogenetic importance and therapeutic implications of NF‐κB in lymphoid malignancies
KH Lim, Y Yang, LM Staudt
Immunological reviews 246 (1), 359-378, 2012
Tumor–stroma IL1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer
D Zhang, L Li, H Jiang, Q Li, A Wang-Gillam, J Yu, R Head, J Liu, ...
Cancer research 78 (7), 1700-1712, 2018
Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies
A Teague, KH Lim, A Wang-Gillam
Therapeutic advances in medical oncology 7 (2), 68-84, 2015
Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a …
A Cercek, T Boerner, BR Tan, JF Chou, M Gönen, TM Boucher, ...
JAMA oncology 6 (1), 60-67, 2020
Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA
KH Lim, DC Brady, DF Kashatus, BB Ancrile, CJ Der, AD Cox, ...
Molecular and cellular biology 30 (2), 508-523, 2010
Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer
A Bulle, KH Lim
Signal Transduction and Targeted Therapy 5 (1), 249, 2020
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion
H Jiang, X Liu, BL Knolhoff, S Hegde, KB Lee, H Jiang, RC Fields, ...
Gut 69 (1), 122-132, 2020
Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?
KH Lim, E Chung, A Khan, D Cao, D Linehan, E Ben-Josef, ...
The oncologist 17 (2), 192-200, 2012
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
H Sun, S Cao, RJ Mashl, CK Mo, S Zaccaria, MC Wendl, SR Davies, ...
Nature communications 12 (1), 5086, 2021
Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis
SH Issaq, KH Lim, CM Counter
Molecular Cancer Research 8 (2), 223-231, 2010
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20